GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Tax Expense

Heidelberg Pharma AG (XTER:HPHA) Tax Expense : €-0.18 Mil (TTM As of May. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Tax Expense?

Heidelberg Pharma AG's tax expense for the months ended in May. 2024 was €-0.05 Mil. Its tax expense for the trailing twelve months (TTM) ended in May. 2024 was €-0.18 Mil.


Heidelberg Pharma AG Tax Expense Historical Data

The historical data trend for Heidelberg Pharma AG's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Tax Expense Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - 1.92 -

Heidelberg Pharma AG Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 -0.28 0.05 -0.05

Heidelberg Pharma AG Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG  (XTER:HPHA) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Heidelberg Pharma AG Tax Expense Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines